Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | JUN | P05412 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL750364 | 0.80 | LMNA (0.36) | LMNAHTTNAPRTKMT2APOLB | |
| SCHEMBL25218114 | 0.76 | ALDH1A1 (0.38) | LMNAHTTKMT2APOLBALDH1A1 | |
| SCHEMBL10389973 | 0.72 | KMT2A (0.33) | LMNAHTTKMT2APOLBALDH1A1 | |
| SCHEMBL456927 | 0.69 | NPC1 (0.47) | KMT2APOLBALDH1A1GAAMAPT | |
| SCHEMBL31447802 | 0.69 | NPC1 (0.47) | KMT2APOLBALDH1A1GAAMAPT | |
| SCHEMBL14589044 | 0.68 | KMT2A (0.40) | LMNAKMT2APOLBALDH1A1JUN | |
| SCHEMBL29367162 | 0.68 | — | — | |
| SCHEMBL111337 | 0.68 | — | — | |
| SCHEMBL15390688 | 0.67 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL11725896 | 0.65 | POLB (0.44) | LMNAHTTKMT2APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280955-B1 | CRYSTALLINE FORM OF 6-Ý(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL¨PYRIDAZIN-3-AMINE | ALBANY MOLECULAR RES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9156812-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150191494-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | ALBANY MOLECULAR RESEARCH, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20140275101-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | CURIA GLOBAL, INC. | 2014-09-18 | — | — | US | disclosed |
| US-8445494-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-8420811-B2 | Tetrahydroisoquinolines and intermediates therefor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20130060027-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2429295-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | Albany Molecular Research, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132437-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2009149259-A2 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060027-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | FARS2, TPH1, COQ8A | LMNA 1456/4885HTT 550/4885NAPRT 392/4885 |
| US-20140275101-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | HTR2C, SYNCRIP, SFPQ | LMNA 503/4885HTT 598/4885NAPRT 1235/4885 |
| US-20150191494-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | FARS2, TPH1, COQ8A | LMNA 1456/4885HTT 550/4885NAPRT 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.